- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01627587
A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole
13. juni 2017 opdateret af: GlaxoSmithKline
A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)
This is a two part study.
Part A of the study will evaluate the metabolites of GSK221149 following single and repeat oral dosing and will also assess the pharmacokinetics of GSK221149 when administered with a potent CYP3A4 inhibitor Ketoconazole.
Part B of the study will look at the pharmacokinetics of GSK221149 following a high fat meal.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
46
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Texas
-
Austin, Texas, Forenede Stater, 78744
- GSK Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 45 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Kvinde
Beskrivelse
Inclusion Criteria:
- ALT, alkaline phosphatase and bilirubin less than and equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
- Single [QTc, QTcB or QTcF] less than 450 msec; or QTc less than 480 msec in subjects with Bundle Branch Block.
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Female subjects between 18 and 45 years of age inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of: Child-bearing potential and is abstinent or agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 48 hours post last dose.
- Body weight greater than 50 kg and BMI within the range 19-29.9 kg/m2 (inclusive).
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol/urine cotinine screen.
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummels, exotic citrus fruits, grapefruit hybrids from 7 days prior to the first dose of study medication.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Ketoconazole-Part A
Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
|
Treatment A: 750 mg GSK221149 single dose
Treatment B: 400 mg of Ketoconazole single dose
Treatment C: 100mg of GSK221149 single dose
|
Eksperimentel: Food-Part B
Healthy Female Volunteers of child bearing potential will receive Treament D and E
|
Treatment D: 750 mg of GSK221149 administered fasted
Treatment E: 750 mg of GSK221149 administered with a high fat meal
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Area under the curve, half life
Tidsramme: From Day 1- Day 11 of the study
|
From Day 1- Day 11 of the study
|
Area under the curve, half life, when treate with ketconizole
Tidsramme: Day 1-11
|
Day 1-11
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
12 lead ECGs, safety labs, vital signs, heart rate, blood pressure
Tidsramme: Day 1- Day 11 of the study
|
Day 1- Day 11 of the study
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
12. december 2011
Primær færdiggørelse (Faktiske)
9. februar 2012
Studieafslutning (Faktiske)
9. februar 2012
Datoer for studieregistrering
Først indsendt
14. juni 2012
Først indsendt, der opfyldte QC-kriterier
21. juni 2012
Først opslået (Skøn)
26. juni 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
15. juni 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
13. juni 2017
Sidst verificeret
1. juni 2017
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Graviditetskomplikationer
- Obstetriske arbejdskomplikationer
- Obstetrisk arbejde, for tidligt
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Enzymhæmmere
- Hormoner, hormonsubstitutter og hormonantagonister
- Cytokrom P-450 CYP3A-hæmmere
- Cytokrom P-450 enzymhæmmere
- Hormonantagonister
- Antifungale midler
- Steroidsyntesehæmmere
- 14-alfa-demethylasehæmmere
- Ketoconazol
Andre undersøgelses-id-numre
- 115893
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokumenter
-
Klinisk undersøgelsesrapport
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Formular til informeret samtykke
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datasætspecifikation
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Annoteret sagsbetænkningsformular
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisk analyseplan
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokol
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Individuelt deltagerdatasæt
Informations-id: 115893Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Obstetrisk arbejde, for tidligt
-
Assiut UniversityIkke rekrutterer endnuFremskridt for Labour
-
Göteborg UniversitySahlgrenska University Hospital, Sweden; Ryhov County HospitalAfsluttetLangsom Labour FremgangSverige
-
University of SaskatchewanAfsluttetPrematur Prematur ruptur af føtale membranerCanada
-
Medical University of ViennaThe Obstetrics and Gynaecology Clinic Narodni FrontTrukket tilbagePrematur Prematur ruptur af føtale membranerØstrig
-
The University of Texas Medical Branch, GalvestonRekrutteringPrematur Prematur Ruptur af Membraner (PPROM)Forenede Stater
-
Region SkaneSuspenderet
-
Hadassah Medical OrganizationAfsluttetSæde præsentation; Før LabourIsrael
-
Seoul National University HospitalAfsluttetFor tidligt arbejde | Prematur Prematur Ruptur af Membran (PPROM)Korea, Republikken
-
Nicole OchsenbeinUniversity of ZurichUkendtGraviditet | Præeklampsi | HELLP syndrom | Prematur Prematur ruptur af føtale membranerSchweiz
-
University Hospital, Clermont-FerrandBiosynex CompanyRekrutteringFor tidlig brud på membranenFrankrig
Kliniske forsøg med GSK221149 750 mg
-
RH NanopharmaceuticalsCenter for Bioequivalence Studies and Clinical ResearchAfsluttetFarmakokinetik | Tolerabilitet | SikkerhedPakistan
-
Mylan Pharmaceuticals IncAfsluttetSund og raskForenede Stater
-
Janssen Pharmaceutical K.K.AfsluttetRespiratoriske syncytielle virusinfektionerJapan
-
GlaxoSmithKlineAfsluttetFor tidlig ejakulation | Obstetrisk arbejde, for tidligtForenede Stater
-
Celon Pharma SANational Center for Research and Development, PolandAfsluttetSunde frivilligePolen
-
Mylan Pharmaceuticals IncAfsluttetSund og raskForenede Stater
-
NeuroBo Pharmaceuticals Inc.Afsluttet